In this podcast, Dr. Aly-Khan Lalani and Dr. Peter Black discuss the latest advancements in treatment for patients with muscle-invasive bladder cancer, the clinical efficacy of newly available treatment options in Canada, and treatment selection and management considerations for treatment regimens in Canada.
Podcast Host Disclosures:
Dr. Black has received honoraria from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Biosyent, Bristol- Myers Squibb, EMD-Serono, Ferring, Janssen Oncology, Merck, Nanology, Nonagen, Pfizer, Prokarium, Protara, QED, Roche Canada, Sanofi Canada, STIMIT, Urogen Pharma and Verity
Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).
Accreditation:
This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits.